On Thursday shares of Genworth Financial, Inc. (NYSE:GNW) closed at $8.25. Company’s sales growth for last 5 years was 1.10% and EPS growth for next 5 years is recorded as 5.00%. Analysts at Jefferies Group increased their target price on shares of Genworth Financial Inc (NYSE:GNW) from $10.00 to $12.00 in a research report issued to clients and investors on Wednesday. The firm currently has a “buy” rating on the stock. Jefferies Group’s target price indicates a potential upside of 44.06% from the company’s current price.
Cellular Biomedicine Group Inc. (NASDAQ:CBMG) in last trading activity increased 11.76% to close at $26.70. Company weekly performance is 8.85% while its quarterly performance stands at 42.63%. Cellular Biomedicine Group Inc. (NASDAQ:CBMG) is -45.51% away from its 52 week high. On April 30, Cellular Biomedicine Group Inc. (Nasdaq:CBMG) announced the appointment of Scott J. Antonia, M.D, Ph.D. and Guoping Fan, Ph.D., as members of the newly established Scientific Advisory Board. Dr. Antonia will advise the company on immuno-oncology and Dr. Fan will advise the company on stem cell technology and its applications.
On last trading day B/E Aerospace Inc. (NASDAQ:BEAV) decreased -0.51% to close at $59.06. Its volatility for the week is 1.80% while volatility for the month is 1.80%. BEAV’s sales growth for past 5 years was 6.00% and its EPS growth for past 5 years was -17.40%. B/E Aerospace Inc. (NASDAQ:BEAV) monthly performance is -5.96%. B/E Aerospace, Inc. (NASDAQ: BEAV) said its board of directors declared a quarterly dividend of USD0.19 per outstanding share of the company´s common stock. The dividend is payable on July 6, 2015 to shareholders of record at the close of business on May 18, 2015.
R.R. Donnelley & Sons Company (NASDAQ:RRD) has 2.10% insider ownership while its institutional ownership stands at 89.40%. In last trading activity company’s stock closed at $18.06. RR Donnelley & Sons Company (NASDAQ:RRD) reported financial results for the first quarter of 2015. Net sales in the quarter were $2.7 billion, up $72.3 million, or 2.7 percent, from the first quarter of 2014, largely due to the acquisitions of Consolidated Graphics and the North American operations of Esselte.
On last trading day Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) decreased -0.30% to close at $468.62. Its volatility for the week is 2.75% while volatility for the month is 2.70%. REGN’s sales growth for past 5 years was 49.40% and its EPS growth for past 5 years was 41.20%. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) monthly performance is 3.40%. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has reported an 11.30 percent rise in profit for the quarter ended Mar. 31, 2015. The company has earned $76.02 million, or $0.66 a share in the quarter, compared with $68.30 million, or $0.61 a share for the same period last year.